GlassScriptPhysician profile
Mark H Scheutzow
NPI 1336403872
$4,407.68
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,912 · 2020: $378 · 2021: $981 · 2022: $137.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $2,916.46 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $437.92 | 2019-2022 | |
| Lundbeck LLC | $318.25 | 2020-2022 | |
| Abbvie INC. | $208.03 | 2021-2022 | |
| Uswm, LLC | $80.69 | 2021 | |
| Collegium Pharmaceutical, INC. | $78.55 | 2021-2022 | |
| Orexo US, INC. | $59.97 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.77 | 2020-2022 | |
| Pfizer INC. | $37.45 | 2021 | |
| Sunovion Pharmaceuticals INC. | $36.59 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $33.16 | 2021 | |
| Indivior INC. | $30.93 | 2021 | |
| Vanda Pharmaceuticals INC. | $28.14 | 2019 | |
| Biodelivery Sciences International, INC. | $27.04 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.71 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $18.29 | 2022 | |
| Virtus Pharmaceuticals LLC | $13.87 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Scheutzow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.